Profile data is unavailable for this security.
About the company
Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Its lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR), directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation and the immunosuppressive TGF-b signaling within the tumor microenvironment. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need. Its platform is designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site.
- Revenue in USD (TTM)0.00
- Net income in USD-121.52m
- Incorporated2018
- Employees55.00
- LocationBicara Therapeutics Inc116 Huntington Avenue Suite 703BOSTON 02116United StatesUSA
- Phone+1 (617) 468-4219
- Fax+1 (302) 655-5049
- Websitehttps://www.bicara.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Personalis Inc | 69.10m | -73.88m | 765.49m | 229.00 | -- | 4.46 | -- | 11.08 | -0.8761 | -0.8761 | 0.8189 | 1.93 | 0.2863 | 7.71 | 4.96 | 301,759.80 | -30.61 | -29.82 | -36.03 | -34.69 | 26.67 | 28.44 | -106.92 | -105.71 | 4.69 | -- | 0.0133 | -- | 15.15 | 5.35 | 24.94 | -- | -28.17 | -- |
| MiMedx Group Inc | 393.44m | 40.83m | 765.69m | 837.00 | 18.93 | 3.20 | 13.80 | 1.95 | 0.273 | 0.273 | 2.63 | 1.61 | 1.40 | 2.79 | 5.95 | 470,062.10 | 14.51 | 2.94 | 17.63 | 3.89 | 81.99 | 83.00 | 10.38 | 2.07 | 3.95 | -- | 0.0708 | -- | 8.52 | 3.12 | -24.73 | -- | -5.37 | -- |
| Janux Therapeutics Inc | 10.00m | -101.90m | 789.74m | 74.00 | -- | 0.8084 | -- | 78.97 | -1.67 | -1.67 | 0.1649 | 16.24 | 0.0116 | -- | -- | 135,135.10 | -11.85 | -13.75 | -12.17 | -14.23 | -- | -- | -1,018.95 | -743.21 | -- | -- | 0.00 | -- | 30.99 | -- | -18.36 | -- | -- | -- |
| YD Bio Ltd | -100.00bn | -100.00bn | 789.84m | 5.00 | -- | 155.23 | -- | -- | -- | -- | -- | 0.0722 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.36 | -- | 0.0124 | -- | 45.76 | -- | -10,509.73 | -- | -- | -- |
| Omeros Corp | 0.00 | -121.24m | 791.96m | 202.00 | -- | -- | -- | -- | -2.04 | -2.02 | 0.00 | -3.15 | 0.00 | -- | -- | 0.00 | -48.59 | -50.90 | -66.86 | -63.20 | -- | -- | -- | -- | -- | -- | 2.72 | -- | -- | -- | -4.41 | -- | -13.15 | -- |
| Maravai Lifesciences Holdings Inc | 192.28m | -121.24m | 797.81m | 550.00 | -- | 3.25 | -- | 4.15 | -0.8442 | -0.8442 | 1.34 | 0.961 | 0.1808 | 3.18 | 7.48 | 337,338.60 | -20.14 | 8.27 | -27.68 | 10.45 | 20.86 | 72.61 | -111.42 | 25.48 | 4.56 | -7.37 | 0.4288 | 0.00 | -10.30 | 12.61 | -21.69 | -- | 12.69 | -- |
| Arbutus Biopharma Corp | 14.61m | -42.28m | 800.07m | 44.00 | -- | 10.32 | -- | 54.78 | -0.2219 | -0.2219 | 0.0764 | 0.4032 | 0.1227 | -- | 11.62 | 331,954.50 | -35.50 | -44.03 | -39.50 | -49.46 | -- | -- | -289.45 | -433.59 | -- | -- | 0.0454 | -- | -65.98 | 0.5268 | 4.02 | -- | -20.93 | -- |
| Annexon Inc | 0.00 | -208.88m | 810.90m | 99.00 | -- | 4.00 | -- | -- | -1.39 | -1.39 | 0.00 | 1.40 | 0.00 | -- | -- | 0.00 | -68.11 | -42.65 | -76.07 | -45.54 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2.95 | -- | -43.78 | -- |
| MapLight Therapeutics Inc | 0.00 | -92.43m | 811.72m | 109.00 | -- | -- | -- | -- | -2.23 | -2.23 | 0.00 | 1.54 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -39.26 | -- | -- | -- |
| Bicara Therapeutics Inc | 0.00 | -121.52m | 820.09m | 55.00 | -- | 2.03 | -- | -- | -5.03 | -5.03 | 0.00 | 7.38 | 0.00 | -- | -- | 0.00 | -25.61 | -- | -26.61 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.80 | -- | -- | -- |
| BIOAGE Labs Inc | 5.92m | -75.79m | 842.88m | 62.00 | -- | 2.61 | -- | 142.45 | -2.04 | -2.04 | 0.1594 | 7.74 | 0.0184 | -- | -- | 95,435.48 | -23.59 | -- | -25.31 | -- | -- | -- | -1,280.90 | -- | -- | -- | 0.0147 | -- | -- | -- | -11.36 | -- | -- | -- |
| Arvinas Inc | 312.30m | -58.50m | 863.17m | 430.00 | -- | 1.69 | -- | 2.76 | -0.8048 | -0.8048 | 4.30 | 7.97 | 0.3105 | -- | 22.63 | 726,279.10 | -5.82 | -20.58 | -7.36 | -25.05 | -- | -- | -18.73 | -211.50 | -- | -- | 0.0007 | -- | 235.54 | 43.71 | 45.85 | -- | -22.02 | -- |
| BridgeBio Oncology Therapeutics Inc | 0.00 | 4.72m | 867.08m | -- | 54.31 | 1.35 | -- | -- | 0.1996 | 0.1996 | 0.00 | 8.05 | 0.00 | -- | -- | -- | 2.44 | -- | 2.45 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18,328.62 | -- | -- | -- |
| Arrivent Biopharma Inc | 0.00 | -151.40m | 870.21m | 52.00 | -- | 2.82 | -- | -- | -4.24 | -4.24 | 0.00 | 7.47 | 0.00 | -- | -- | 0.00 | -48.90 | -- | -51.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -16.09 | -- | -- | -- |
| SS Innovations International Inc | 33.57m | -17.11m | 877.10m | 378.00 | -- | 22.12 | -- | 26.12 | -0.0959 | -0.0959 | 0.1822 | 0.2048 | 0.6253 | 1.19 | 5.09 | 88,820.32 | -31.86 | -77.47 | -50.87 | -137.45 | 48.25 | 23.69 | -50.96 | -169.09 | 1.34 | -- | 0.2025 | -- | 251.46 | -- | 8.27 | -- | 67.53 | -- |
Data as of Feb 11 2026. Currency figures normalised to Bicara Therapeutics Inc's reporting currency: US Dollar USD
44.63%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 30 Sep 2025 | 6.96m | 12.75% |
| Vestal Point Capital LPas of 30 Sep 2025 | 5.10m | 9.35% |
| Deep Track Capital LPas of 30 Sep 2025 | 2.43m | 4.45% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 2.09m | 3.82% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.95m | 3.57% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2025 | 1.71m | 3.13% |
| Blackstone Alternative Asset Management LPas of 30 Sep 2025 | 1.22m | 2.24% |
| FIAM LLCas of 30 Sep 2025 | 1.06m | 1.94% |
| Millennium Management LLCas of 30 Sep 2025 | 1.01m | 1.86% |
| Geode Capital Management LLCas of 30 Sep 2025 | 831.21k | 1.52% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
